Celcuity (CELC) is back in focus after reporting pivotal Phase 3 VIKTORIA-1 data for gedatolisib in HR-positive, HER2-negative advanced breast cancer, expanding the VIKTORIA-2 program and preparing ...
VIKTORIA-2 Trial Evolves to Evaluate Gedatolisib in Endocrine-Sensitive and -Resistant Breast Cancer
Significant protocol amendments have been made to the ongoing phase 3 VIKTORIA-2 clinical trial (NCT06757634).The study, ...
On Thursday, Celcuity Inc. CELC announced amendments to its Phase 3 VIKTORIA-2 clinical trial evaluating gedatolisib as a ...
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Celcuity (CELC) and Rubicon Organics (ROMJF) with bullish sentiments. According to TipRanks.com, McCammon ...
Q1 2026 call: gedatolisib FDA PDUFA July 17, ASCO VIKTORIA-1 data, VIKTORIA-2 expansion & cash runway—read now.
Celcuity (NASDAQ:CELC) reported a wider first-quarter loss as the biotechnology company increased spending tied to commercial launch preparations and continued development of gedatolisib, its ...
MINNEAPOLIS - Celcuity Inc. (NASDAQ:CELC) reported a first-quarter loss of -$0.97 per share, beating analyst estimates of -$1.04 per share. The clinical-stage biotechnology company reported no revenue ...
Celcuity shares rose after the Phase 3 trial of a treatment for breast cancer was expanded to include endocrine-sensitive patients. Shares company rose 9.7% to $136.59 in late morning trading on ...
(Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced updates to the Phase 3 ...
A replay of the webcast will be available on the Celcuity website following the live event. Celcuity is a clinical-stage biotechnology company pursuing the development of targeted therapies for the ...
If you are trying to figure out whether Celcuity stock still offers value after a strong run, the starting point is understanding what the current price is really pricing in. Celcuity recently closed ...
HR+/HER2- breast cancer is the most common subtype of the disease, representing approximately 70% of all breast cancer cases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results